• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从影像解读到治疗反应评估的按癌症类型划分的PET标准:超越FDG PET评分

PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score.

作者信息

Dondi Francesco, Lazzarato Achille, Gorica Joana, Guglielmo Priscilla, Borgia Francesca, Filice Rossella, Vento Antonio, Pacella Sara, Camedda Riccardo, Caracciolo Matteo, De Feo Maria Silvia, Mammucci Paolo, Frantellizzi Viviana, Ortolan Naima, Fiasconaro Elisa, Urso Luca, Evangelista Laura, Laudicella Riccardo, Santo Giulia

机构信息

Nuclear Medicine, ASST Spedali Civili di Brescia, 25123 Brescia, Italy.

Unit of Nuclear Medicine, Department of Medicine, Surgery and Pharmacy, Università degli Studi di Sassari, 07100 Sassari, Italy.

出版信息

Life (Basel). 2023 Feb 22;13(3):611. doi: 10.3390/life13030611.

DOI:10.3390/life13030611
PMID:36983767
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC10057339/
Abstract

BACKGROUND

in recent years, the role of positron emission tomography (PET) and PET/computed tomography (PET/CT) has emerged as a reliable diagnostic tool in a wide variety of pathological conditions. This review aims to collect and review PET criteria developed for interpretation and treatment response assessment in cases of non-[F]fluorodeoxyglucose ([F]FDG) imaging in oncology.

METHODS

A wide literature search of the PubMed/MEDLINE, Scopus and Google Scholar databases was made to find relevant published articles about non-[F]FDG PET response criteria.

RESULTS

The comprehensive computer literature search revealed 183 articles. On reviewing the titles and abstracts, 149 articles were excluded because the reported data were not within the field of interest. Finally, 34 articles were selected and retrieved in full-text versions.

CONCLUSIONS

available criteria are a promising tool for the interpretation of non-FDG PET scans, but also to assess the response to therapy and therefore to predict the prognosis. However, oriented clinical trials are needed to clearly evaluate their impact on patient management.

摘要

背景

近年来,正电子发射断层扫描(PET)及PET/计算机断层扫描(PET/CT)在多种病理状况下已成为可靠的诊断工具。本综述旨在收集并回顾肿瘤学中非[F]氟脱氧葡萄糖([F]FDG)成像的PET标准,用于解读及治疗反应评估。

方法

对PubMed/MEDLINE、Scopus及谷歌学术数据库进行广泛文献检索,以查找有关非[F]FDG PET反应标准的相关已发表文章。

结果

全面的计算机文献检索共找到183篇文章。在审阅标题和摘要后,排除了149篇文章,因为报告的数据不在感兴趣的领域内。最后,选择了34篇文章并获取了全文版本。

结论

现有标准是解读非FDG PET扫描的有前景的工具,也可用于评估治疗反应,进而预测预后。然而,需要有针对性的临床试验来明确评估其对患者管理的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7c5/10057339/2ea450b8eb8a/life-13-00611-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7c5/10057339/cfefaa0e4de4/life-13-00611-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7c5/10057339/2ea450b8eb8a/life-13-00611-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7c5/10057339/cfefaa0e4de4/life-13-00611-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7c5/10057339/2ea450b8eb8a/life-13-00611-g002.jpg

相似文献

1
PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score.从影像解读到治疗反应评估的按癌症类型划分的PET标准:超越FDG PET评分
Life (Basel). 2023 Feb 22;13(3):611. doi: 10.3390/life13030611.
2
F-FDG PET or PET/CT role in plasmacytoma: A systematic review.浆细胞瘤中 F-FDG PET 或 PET/CT 的作用:系统评价。
Rev Esp Med Nucl Imagen Mol (Engl Ed). 2020 Jul-Aug;39(4):220-224. doi: 10.1016/j.remn.2019.12.004. Epub 2020 Jun 7.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
5
The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG-PET/CT)在结直肠癌术前分期中的价值:系统评价和经济评估。
Health Technol Assess. 2011 Sep;15(35):1-192, iii-iv. doi: 10.3310/hta15350.
6
Radiolabelled PSMA PET/CT in breast cancer. A systematic review.放射性标记 PSMA PET/CT 在乳腺癌中的应用。系统评价。
Nucl Med Rev Cent East Eur. 2020;23(1):32-35. doi: 10.5603/NMR.2020.0004.
7
The role of 18F-FDG-PET and PET/CT in patients with sarcoidosis: an updated evidence-based review.18F-FDG-PET和PET/CT在结节病患者中的作用:一项基于证据的最新综述。
Acad Radiol. 2014 May;21(5):675-84. doi: 10.1016/j.acra.2014.01.008.
8
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria.使用 PSMA PET/CT 测量转移性去势抵抗性前列腺癌的反应:RECIST 1.1、aPCWG3、aPERCIST、PPP 和 RECIP 1.0 标准的比较。
Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4271-4281. doi: 10.1007/s00259-022-05882-x. Epub 2022 Jun 29.
9
How to perform a comprehensive search for FDG-PET literature.如何全面检索氟代脱氧葡萄糖正电子发射断层扫描(FDG-PET)文献。
Eur J Nucl Med. 2000 Jan;27(1):91-7. doi: 10.1007/pl00006669.
10
F-FDG PET or PET/CT in Mantle Cell Lymphoma.弥漫大 B 细胞淋巴瘤的 F-FDG PET 或 PET/CT。
Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):422-430. doi: 10.1016/j.clml.2020.01.018. Epub 2020 Feb 4.

引用本文的文献

1
The Role of [18F]FDG PET Imaging for the Assessment of Pulmonary Lymphangitic Carcinomatosis: A Comprehensive Narrative Literature Review.[18F]氟代脱氧葡萄糖正电子发射断层扫描成像在评估肺淋巴管癌病中的作用:一项全面的叙述性文献综述
Diagnostics (Basel). 2025 Jun 26;15(13):1626. doi: 10.3390/diagnostics15131626.
2
The Role of 11C-Methionine PET Imaging for the Evaluation of Lymphomas: A Systematic Review.11C-蛋氨酸PET成像在淋巴瘤评估中的作用:一项系统综述
Hematol Rep. 2024 Nov 27;16(4):752-768. doi: 10.3390/hematolrep16040072.
3
The Role of PSMA PET Imaging in the Classification of the Risk of Prostate Cancer Patients: A Systematic Review on the Insights to Guide an Active Surveillance Approach.

本文引用的文献

1
Dual [Ga]DOTATATE and [F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score.多中心验证 NETPET 评分:转移性胃肠胰神经内分泌肿瘤患者的双[Ga]DOTATATE 和 [F]FDG PET/CT。
Br J Cancer. 2023 Feb;128(4):549-555. doi: 10.1038/s41416-022-02061-5. Epub 2022 Nov 25.
2
Association of True Positivity with Serum Prostate-Specific Antigen Levels and Other Clinical Factors in Indeterminate PSMA-RADS-3A Lesions Identified on F-DCFPyL PET/CT Scans.在 F-DCFPyL PET/CT 扫描中发现的 PSMA-RADS-3A 不确定病变中,真阳性与血清前列腺特异性抗原水平及其他临床因素的相关性。
Tomography. 2022 Oct 27;8(6):2639-2647. doi: 10.3390/tomography8060220.
3
前列腺特异性膜抗原(PSMA)正电子发射断层扫描(PET)成像在前列腺癌患者风险分类中的作用:关于指导主动监测方法的见解的系统评价
Cancers (Basel). 2024 Mar 11;16(6):1122. doi: 10.3390/cancers16061122.
4
Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot Study.放射增敏有利于高增殖性神经内分泌恶性肿瘤患者对肽受体放射性核素治疗的反应:来自临床初步研究的初步证据。
Clin Nucl Med. 2024 Mar 1;49(3):207-214. doi: 10.1097/RLU.0000000000005006. Epub 2024 Jan 23.
5
Emerging Role of [F]FLT PET/CT in Lymphoid Malignancies: A Review of Clinical Results.[F]氟代胸腺嘧啶核苷正电子发射断层扫描/计算机断层扫描在淋巴系统恶性肿瘤中的新作用:临床结果综述
Hematol Rep. 2024 Jan 11;16(1):32-41. doi: 10.3390/hematolrep16010004.
Glucose Metabolism Modification Induced by Radioligand Therapy with [Lu]Lu/[Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial.
[镥]镥/[钇]钇-奥曲肽放射性配体治疗对晚期神经内分泌肿瘤葡萄糖代谢的影响:FENET-2016试验中的一项前瞻性初步研究
Pharmaceutics. 2022 Sep 22;14(10):2009. doi: 10.3390/pharmaceutics14102009.
4
[Lu]Lu-PSMA-617 (Pluvicto): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer.[镥]镥-PSMA-617(普卢维托):首个获美国食品药品监督管理局批准用于治疗前列腺癌的放射治疗药物。
Pharmaceuticals (Basel). 2022 Oct 20;15(10):1292. doi: 10.3390/ph15101292.
5
Evaluation of [ Ga]Ga-PSMA-I&T PET/CT with additional late scans of the pelvis in prostate-specific antigen recurrence using the PROMISE criteria.使用PROMISE标准,对[镓]镓-PSMA-I&T PET/CT进行评估,并对前列腺特异性抗原复发患者的骨盆进行额外的晚期扫描。
EJNMMI Res. 2022 Oct 9;12(1):66. doi: 10.1186/s13550-022-00938-3.
6
PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?前列腺特异性膜抗原放射性配体摄取作为实体肿瘤新生血管生成的生物标志物:诊断还是治疗诊断因素?
Cancers (Basel). 2022 Aug 21;14(16):4039. doi: 10.3390/cancers14164039.
7
18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready?18F-胆碱PET/CT或PET/MR与前列腺癌全身治疗反应评估:我们准备好了吗?
Clin Transl Imaging. 2022;10(6):687-695. doi: 10.1007/s40336-022-00515-7. Epub 2022 Jul 28.
8
Indeterminate skeletal and lymph node lesion on 18F PSMA 1007 PET/CT scanning: lessons from a review at 12 months with PSMA-RADS.18F PSMA 1007 PET/CT 扫描发现不确定的骨骼和淋巴结病变:PSMA-RADS 12 个月复查的经验教训。
Nucl Med Commun. 2022 Sep 1;43(9):1034-1041. doi: 10.1097/MNM.0000000000001600. Epub 2022 Jul 14.
9
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria.使用 PSMA PET/CT 测量转移性去势抵抗性前列腺癌的反应:RECIST 1.1、aPCWG3、aPERCIST、PPP 和 RECIP 1.0 标准的比较。
Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4271-4281. doi: 10.1007/s00259-022-05882-x. Epub 2022 Jun 29.
10
Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT.基于Choi、RECIST和生长抑素受体PET/CT标准对肽受体放射性核素治疗反应及反应预测的比较
Pharmaceutics. 2022 Jun 16;14(6):1278. doi: 10.3390/pharmaceutics14061278.